RATIONALE AND OBJECTIVES: The aim of this study was to assess the feasibility of 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) to systematically detect and quantify differential effects of chronic tobacco use in organs of the whole body. MATERIALS AND METHODS: Twenty healthy male subjects (10 nonsmokers and 10 chronic heavy smokers) were enrolled. Subjects underwent whole-body FDG-PET/CT, diagnostic unenhanced chest CT, mini-mental state examination, urine testing for oxidative stress, and serum testing. The organs of interest (thyroid, skin, skeletal muscle, aorta, heart, lung, adipose tissue, liver, spleen, brain, lumbar spinal bone marrow, and testis) were analyzed on FDG-PET/CT images to determine their metabolic activities using standardized uptake value (SUV) or metabolic volumetric product (MVP). Measurements were compared between subject groups using two-sample t tests or Wilcoxon rank-sum tests as determined by tests for normality. Correlational analyses were also performed. RESULTS: FDG-PET/CT revealed significantly decreased metabolic activity of lumbar spinal bone marrow (MVPmean: 29.8 ± 9.7 cc vs 40.8 ± 11.6 cc, P = 0.03) and liver (SUVmean: 1.8 ± 0.2 vs 2.0 ± 0.2, P = 0.049) and increased metabolic activity of visceral adipose tissue (SUVmean: 0.35 ± 0.10 vs 0.26 ± 0.06, P = 0.02) in chronic smokers compared to nonsmokers. Normalized visceral adipose tissue volume was also significantly decreased (P = 0.04) in chronic smokers. There were no statistically significant differences in the metabolic activity of other assessed organs. CONCLUSIONS: Subclinical organ effects of chronic tobacco use are detectable and quantifiable on FDG-PET/CT. FDG-PET/CT may, therefore, play a major role in the study of systemic toxic effects of tobacco use in organs of the whole body for clinical or research purposes.
RATIONALE AND OBJECTIVES: The aim of this study was to assess the feasibility of 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) to systematically detect and quantify differential effects of chronic tobacco use in organs of the whole body. MATERIALS AND METHODS: Twenty healthy male subjects (10 nonsmokers and 10 chronic heavy smokers) were enrolled. Subjects underwent whole-body FDG-PET/CT, diagnostic unenhanced chest CT, mini-mental state examination, urine testing for oxidative stress, and serum testing. The organs of interest (thyroid, skin, skeletal muscle, aorta, heart, lung, adipose tissue, liver, spleen, brain, lumbar spinal bone marrow, and testis) were analyzed on FDG-PET/CT images to determine their metabolic activities using standardized uptake value (SUV) or metabolic volumetric product (MVP). Measurements were compared between subject groups using two-sample t tests or Wilcoxon rank-sum tests as determined by tests for normality. Correlational analyses were also performed. RESULTS:FDG-PET/CT revealed significantly decreased metabolic activity of lumbar spinal bone marrow (MVPmean: 29.8 ± 9.7 cc vs 40.8 ± 11.6 cc, P = 0.03) and liver (SUVmean: 1.8 ± 0.2 vs 2.0 ± 0.2, P = 0.049) and increased metabolic activity of visceral adipose tissue (SUVmean: 0.35 ± 0.10 vs 0.26 ± 0.06, P = 0.02) in chronic smokers compared to nonsmokers. Normalized visceral adipose tissue volume was also significantly decreased (P = 0.04) in chronic smokers. There were no statistically significant differences in the metabolic activity of other assessed organs. CONCLUSIONS: Subclinical organ effects of chronic tobacco use are detectable and quantifiable on FDG-PET/CT. FDG-PET/CT may, therefore, play a major role in the study of systemic toxic effects of tobacco use in organs of the whole body for clinical or research purposes.
Authors: Marietta Stadler; Larissa Tomann; Angela Storka; Michael Wolzt; Slobodan Peric; Christian Bieglmayer; Giovanni Pacini; Suzanne L Dickson; Helmut Brath; Paul Bech; Rudolf Prager; Márta Korbonits Journal: Eur J Endocrinol Date: 2014-02-01 Impact factor: 6.664
Authors: Thomas Christen; Yuri Sheikine; Viviane Z Rocha; Shelley Hurwitz; Allison B Goldfine; Marcelo Di Carli; Peter Libby Journal: JACC Cardiovasc Imaging Date: 2010-08
Authors: Tobias Schroeder; Marcos F Vidal Melo; Guido Musch; R Scott Harris; Tilo Winkler; Jose G Venegas Journal: J Nucl Med Date: 2007-03 Impact factor: 10.057
Authors: Stefanie A de Boer; Daan S Spoor; Riemer H J A Slart; Douwe J Mulder; Melanie Reijrink; Ronald J H Borra; Gerbrand M Kramer; Otto S Hoekstra; Ronald Boellaard; Marcel J Greuter Journal: Mol Imaging Biol Date: 2019-02 Impact factor: 3.488
Authors: Phoebe B McAuliffe; Abhishek A Desai; Ankoor A Talwar; Robyn B Broach; Jesse Y Hsu; Joseph M Serletti; Tiange Liu; Yubing Tong; Jayaram K Udupa; Drew A Torigian; John P Fischer Journal: Ann Surg Date: 2022-07-15 Impact factor: 13.787
Authors: Dima A Hammoud; Sanhita Sinharay; Sally Steinbach; Paul G Wakim; Katrina Geannopoulos; Katherine Traino; Amit K Dey; Edmund Tramont; Stanley I Rapoport; Joseph Snow; Nehal N Mehta; Bryan R Smith; Avindra Nath Journal: Neurology Date: 2018-09-26 Impact factor: 9.910